CESAR Awarded Five-Year NIDA Funding to Develop the National Drug Early Warning System (NDEWS)
The National Drug Early Warning System (NDEWS) will monitor emerging trends to enable health experts to respond quickly to potential outbreaks of illicit drugs such as heroin and to identify increased use of designer synthetic compounds. For more information, see this special edition of the CESAR FAX, or go to the NIDA Press Release.
Maryland's Successful Community Services Locator Is Now Available for Other Jurisdictions
CESAR would like to work with you to implement a Community Services Locator (CSL) or a secure Inmate Community Services Locator (ICSL) in your area. For more information, see our CSL and ICSL brochures. Check out the Maryland Community Services Locator (MDCSL; www.mdcsl.org) to see a working example of this invaluable tool.
CESAR FAX Special Series on Synthetic Cannabinoids Updated
Stay on top of the most recent research and survey results regarding synthetic cannabinoids with this updated compilation of CESAR FAX issues on the topic.
CESAR Recognized with Research Award
On April 11th, CESAR was presented with Caron's Greater Washington D.C. Region Research Award. This award recognizes an individual or organization who has excelled in the research field, allowing those affected by the disease of addiction to have better, more appropriate treatment made available to them.
CESAR FAX Bound and Indexed Annual Volume Now Available
Have all of the 2013 CESAR FAX issues at your fingertips with this bound volume, indexed by issue number and subject area. To purchase a copy, please mail the order form along with a purchase order or check for $10 to CESAR.
CESAR Pilots New Community Drug Early Warning System (CDEWS)
Emerging drugs of abuse in communities can be rapidly identified by an innovative urine testing system, according to the results of a recently released ONDCP-funded pilot study of the Community Drug Early Warning System (CDEWS). CDEWS is designed to detect emerging drugs by re-testing urine specimens collected for traditional criminal justice system (CJS) drug testing programs, and examining them for emerging drugs of abuse, such as synthetic cannabinoids (SC). The pilot study tested urine specimens from five criminal justice system (CJS) populations in Washington, DC; Prince George’s County, Maryland; and Chesterfield, Virginia for an expanded panel of more than 30 prescription and illicit drugs, including 12 SC metabolites. SC metabolites were detected in all of the populations studied.
A copy of the full report can be found on the ONDCPwebsite. The press release from the University of Maryland can be found online at http://www.umdrightnow.umd.edu/news/innovative-testing-program-detects-emerging-drugs and a short video of CESAR's Director, Dr. Eric Wish, discussing the study is available at http://youtu.be/UqmiI8afxEY.
CESAR FAX Special Series on Buprenorphine Updated
While research indicates that buprenorphine is an effective drug for treating opioid dependence, we feel that the potential for its nonmedical use and related unintended consequences may be going unnoticed. This series of publications on buprenorphine was designed to highlight several indicators of the increased availability, diversion, and misuse of buprenorphine.
UMD Press Release on NDEWS Project
NIDA Press Release on NDEWS Project
CESAR Pilots New Community Drug Early Warning
Diamondback Article on CDEWS
UMD Video of Dr. Wish Discussing CDEWS Findings
Washington Post Article on CDEWS Project
Washington Times Article on CDEWS Project
CESAR Responds to NPR's Story on Buprenorphine